Researchers at Johns Hopkins Medicine found that ophthalmologists and optometrists who received incentives from pharmaceutical companies are twice as likely to prescribe name-brand eye drops for glaucoma instead of generic, less expensive options.
Physicians that receive incentives more likely to prescribe high-cost eye drops: Report
